Cargando…

PALB2 (partner and localizer of BRCA2)

PALB2 (Partner and Localizer of BRCA2) was first identified as a BRCA2-interacting protein. Subsequently, PALB2 has been recognized as a cog in the cellular machinery for DNA repair by homologous recombination (HR). PALB2 also mediates S and G2 DNA damage checkpoints, and has an apparent function in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanenberg, Helmut, Andreassen, Paul R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693662/
https://www.ncbi.nlm.nih.gov/pubmed/31413733
http://dx.doi.org/10.4267/2042/69016
_version_ 1783443721056944128
author Hanenberg, Helmut
Andreassen, Paul R.
author_facet Hanenberg, Helmut
Andreassen, Paul R.
author_sort Hanenberg, Helmut
collection PubMed
description PALB2 (Partner and Localizer of BRCA2) was first identified as a BRCA2-interacting protein. Subsequently, PALB2 has been recognized as a cog in the cellular machinery for DNA repair by homologous recombination (HR). PALB2 also mediates S and G2 DNA damage checkpoints, and has an apparent function in protecting transcriptionally active genes from genotoxic stress. PALB2 also interacts with, is localized by, and functions downstream of BRCA1. Further, PALB2 interacts with other essential effectors of HR, including RAD51 and RAD51C, as well as BRCA2. Consistent with its function in HR and its interaction with key HR proteins, PALB2-deficient cells are hypersensitive to ionizing radiation and DNA interstrand crosslinking agents such as mitomycin C and cisplatin. Mechanistically, PALB2 is required for HR by mediating the recruitment of BRCA2 and the RAD51 recombinase to sites of DNA damage. Similar to bi-allelic loss-of-function mutations of BRCA1, BRCA2, RAD51 and RAD51C, bi-allelic mutations in PALB2 cause Fanconi anemia (FA), a rare childhood disorder which is associated with progressive bone marrow failure, congenital anomalies, and a predisposition to leukemia and solid tumors. Due to their close functional relationship, bi-allelic mutations of PALB2 and BRCA2 cause particularly severe forms of FA, called FANCN and FANCD1, both characterized by severe congenital abnormalities and very early onset of various cancers. This includes acute leukemias, Wilms tumor, medulloblastoma and neuroblastomas. Also, heterozygous germ-line mutations of PALB2, like mutations in several other essential HR genes listed above, yield an increased susceptibility to breast and pancreatic cancer.
format Online
Article
Text
id pubmed-6693662
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-66936622019-08-14 PALB2 (partner and localizer of BRCA2) Hanenberg, Helmut Andreassen, Paul R. Atlas Genet Cytogenet Oncol Haematol Article PALB2 (Partner and Localizer of BRCA2) was first identified as a BRCA2-interacting protein. Subsequently, PALB2 has been recognized as a cog in the cellular machinery for DNA repair by homologous recombination (HR). PALB2 also mediates S and G2 DNA damage checkpoints, and has an apparent function in protecting transcriptionally active genes from genotoxic stress. PALB2 also interacts with, is localized by, and functions downstream of BRCA1. Further, PALB2 interacts with other essential effectors of HR, including RAD51 and RAD51C, as well as BRCA2. Consistent with its function in HR and its interaction with key HR proteins, PALB2-deficient cells are hypersensitive to ionizing radiation and DNA interstrand crosslinking agents such as mitomycin C and cisplatin. Mechanistically, PALB2 is required for HR by mediating the recruitment of BRCA2 and the RAD51 recombinase to sites of DNA damage. Similar to bi-allelic loss-of-function mutations of BRCA1, BRCA2, RAD51 and RAD51C, bi-allelic mutations in PALB2 cause Fanconi anemia (FA), a rare childhood disorder which is associated with progressive bone marrow failure, congenital anomalies, and a predisposition to leukemia and solid tumors. Due to their close functional relationship, bi-allelic mutations of PALB2 and BRCA2 cause particularly severe forms of FA, called FANCN and FANCD1, both characterized by severe congenital abnormalities and very early onset of various cancers. This includes acute leukemias, Wilms tumor, medulloblastoma and neuroblastomas. Also, heterozygous germ-line mutations of PALB2, like mutations in several other essential HR genes listed above, yield an increased susceptibility to breast and pancreatic cancer. 2018-04 /pmc/articles/PMC6693662/ /pubmed/31413733 http://dx.doi.org/10.4267/2042/69016 Text en http://creativecommons.org/licenses/by-nc-nd/2.0/ This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
spellingShingle Article
Hanenberg, Helmut
Andreassen, Paul R.
PALB2 (partner and localizer of BRCA2)
title PALB2 (partner and localizer of BRCA2)
title_full PALB2 (partner and localizer of BRCA2)
title_fullStr PALB2 (partner and localizer of BRCA2)
title_full_unstemmed PALB2 (partner and localizer of BRCA2)
title_short PALB2 (partner and localizer of BRCA2)
title_sort palb2 (partner and localizer of brca2)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693662/
https://www.ncbi.nlm.nih.gov/pubmed/31413733
http://dx.doi.org/10.4267/2042/69016
work_keys_str_mv AT hanenberghelmut palb2partnerandlocalizerofbrca2
AT andreassenpaulr palb2partnerandlocalizerofbrca2